Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Halichondrin B Analog E7389 in Combination With Gemcitabine in Patients With Refractory or Advanced Solid Tumors

NCT00410553 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00410553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00410553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Halichondrin B Analog E7389 in Combination With Gemcitabine in Patients With Refractory or Advanced Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2006
Completion date
October 24, 2012
Enrollment
45 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid neoplasm, recurrent ovarian carcinoma, recurrent uterine corpus carcinoma, stage iii ovarian cancer ajcc v6 and v7, stage iii uterine corpus cancer ajcc v7, stage iv ovarian cancer ajcc v6 and v7, stage iv uterine corpus cancer ajcc v7